CEACAM5 and pancreatic neoplasm: Another study described the use of dual CAR cells against pancreatic cancer by developing an anti-carcinoembryonic antigen (CEA) CAR coupled to a mesothelin-specific CCR (MSLN-4/1BB) [43].